Question 1

What is CJC-1295?

Accepted Answer

CJC-1295 is a laboratory-made copy of growth hormone-releasing hormone, the signal the brain sends to the pituitary gland at the base of the skull. A 2019 analytical paper puts it plainly: CJC-1295 is a peptide-based drug that stimulates the production of growth hormone from the pituitary gland. It is not growth hormone itself, and it does not act in place of it. What it does instead is ask a gland that is already working to release more of what it already makes. A 2026 critical review sorts the field into classes and places CJC-1295 among the growth hormone-releasing hormone analogues alongside sermorelin, apart from growth hormone secretagogues such as ipamorelin. That split matters more than it looks. Anyone weighing the two is weighing two different routes into the same gland, rather than two versions of one compound.

Question 2

What does the DAC in CJC-1295 with DAC mean?

Accepted Answer

The letters stand for Drug Affinity Complex, and the two versions sold under one name differ chemically rather than commercially. A 2019 paper spells out the trick. CJC-1295 incorporates a functional maleimido group at the C-terminus that allows it to covalently bind plasma proteins such as serum albumin. Albumin is the most common protein in blood, and a molecule latched onto it clears far more slowly than one drifting free. The same paper reports that these conjugates have a much greater half-life compared to the unconjugated peptide. They keep growth hormone production going for more than six days in humans after a single administration. A 2026 review lists CJC-1295 with Drug Affinity Complex and CJC-1295 without DAC as two separate entries. Anti-doping chemists split them the same way, building methods for sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex. Without the complex it is the short-acting form. With it, one shot reaches across days.

Question 3

Has CJC-1295 been studied in people?

Accepted Answer

Yes, and the human record is older and much narrower than the current interest in it. The 2006 report that set its profile describes two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 days, run in healthy subjects aged 21 to 61 years. After a single injection there were dose-dependent increases in mean plasma growth hormone by 2- to 10-fold for 6 days or more. A separate 2009 analysis took serum from 11 healthy young adult men before and one week after a CJC-1295 injection, hunting for protein markers rather than for any clinical result. A 2026 scoping review covering CJC-1295 and five related compounds found that 67% of identified publications utilized preclinical animal models. A 2026 orthopaedic review puts the rest of it bluntly, recording that there is a current lack of clinical trials. So people have received it under controlled conditions, and what got watched afterwards was their bloodwork.

Question 4

What happened to the clinical development of CJC-1295?

Accepted Answer

One registered trial carries most of that answer, and it did not finish. The public registry holds a phase 2 entry titled A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity, and its recorded status is terminated. The registry gives the status without a reason, and nothing in the published work explains one either. So what can be said is the fact of the stop, rather than the cause. A 2010 forensic analysis described the pattern that often follows. Several peptide drugs are being manufactured illicitly, and in some cases they are being made available to the public before entering or completing clinical trials. A 2026 review still files growth hormone axis secretagogues such as CJC-1295 as investigational, with uncertain safety profiles and product quality concerns. That is where a compound sits when its testing stops instead of ending.

Question 5

How long does CJC-1295 stay in your body?

Accepted Answer

Longer than most compounds in this category, and the published numbers are specific. The 2006 trials in healthy adults put the estimated half-life of CJC-1295 at 5.8 to 8.1 days, which is the time taken for half of an injected amount to clear. The hormone effects outlast the molecule itself. In those same trials, mean plasma IGF-I went up 1.5- to 3-fold for 9 to 11 days after one injection, and after repeated injections mean IGF-I levels remained above baseline for up to 28 days. The 2019 analytical work supplies the reason: the albumin-bound form keeps growth hormone production going for more than six days in humans after a single administration. Every one of those figures belongs to the DAC version, and nothing in the cited literature puts a comparable number on the version without it.

Question 6

How often was CJC-1295 given in the published studies?

Accepted Answer

The published schedules are experimental settings rather than instructions, and there are only two of them. In the 2006 work, CJC-1295 or placebo was administered subcutaneously in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study. That is the whole published account of how often it has been given to a person. Both trials were built to track hormones rather than to find a workable schedule. A 2026 primer for orthopaedic and sports medicine physicians states the upshot without softening it: information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Amounts, units and the arithmetic of reconstitution sit on the dosage page, next to the study each figure came from.

Question 7

Is CJC-1295 taken orally?

Accepted Answer

Every dose in the published record went in as a shot under the skin. The 2006 trials gave CJC-1295 or placebo subcutaneously. The testing literature handles it as an injected peptide, pulling it back out of blood and urine rather than out of anything swallowed. A 2026 review of injectable peptides in sport left out noninjectable formulations entirely, which tells you how little of that work exists. A 2015 doping-control paper files CJC-1295 among bioactive peptides with an approximate molecular mass of 2-12 kDa, and that method was shown to be applicable to blood and urine samples. No study among the research behind this page has given CJC-1295 by mouth and measured what followed, so an oral version is untested rather than ruled out.

Question 8

What is CJC-1295 reported to be used for?

Accepted Answer

Reported, not demonstrated, and the distinction carries this entire section. A 2026 critical review records that peptides of this class are promoted for muscle growth, fat metabolism, recovery, and anti-inflammatory effects in human users. A 2016 study of 23 online discussion threads about female use found that the choice to use CJC-1295 centred on weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing in human accounts. Every item on both lists is a reported motive. Not one of them is an endpoint that a completed trial of CJC-1295 has measured, which is not the same thing at all. A 2026 review in Sports Medicine adds the complication that makes self-report hard to read, discussing the placebo effect as a mediator of peptide efficacy and how social media amplifies this effect.

Question 9

Does CJC-1295 build muscle?

Accepted Answer

No completed trial has measured muscle size or strength in a person given CJC-1295. The one muscle result in the literature is in animals, and it belongs to a pair rather than to CJC-1295 alone. A 2026 primer reports that CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, while noting that these findings are limited to animal studies. Maximum tetanic tension is the peak force a stimulated muscle can put out in a lab rig. Read what that test asked. It asked whether the pair defends muscle that a steroid is actively wasting, in mice. Whether a healthy adult gains muscle is a different question, and no study we could find has run it. The pair, which the CJC-1295 comparison page traces from the FDA recall vials through to what ipamorelin has on its own, is a separate subject from this one.

Question 10

Does CJC-1295 cause weight gain?

Accepted Answer

No trial among the research behind this page of CJC-1295 has measured body weight, body fat or body composition in a person. The human studies tracked hormones in blood and nothing else: the main outcome measures were peak concentrations and area under the curve of growth hormone and IGF-I, and a 2009 analysis went looking for serum proteins. That gap is worth sitting with, because weight is the outcome most readers arrive asking about. What the literature holds instead is motive and mechanism. A 2016 study reported that the choice to use CJC-1295 centred on weight loss among other reasons, and a 2026 review records that peptides of this class are promoted for fat metabolism, which is a marketing position rather than a trial result. The nearest real finding is the IGF-I rise in healthy adults, and a hormone moving in blood and a body changing shape are different questions.

Question 11

Does CJC-1295 affect testosterone?

Accepted Answer

No study among the research behind this page of CJC-1295 has measured testosterone, in either direction. The two human trials tracked growth hormone and IGF-I, which sit on a different hormonal axis from the one that makes testosterone. That absence answers all three versions of the question people ask, whether CJC-1295 raises it, suppresses it or merely affects it. It is an absence rather than a finding of no effect. The closest the literature comes is a 2026 review of this class, which reports adverse effects spanning endocrine and metabolic disturbances including prolactin and cortisol elevations, appetite changes, and dysglycaemia, meaning blood sugar that will not hold steady. Prolactin and cortisol are hormones, so this is not territory where nothing moves. Testosterone has simply not been looked at.

Question 12

What happens after someone stops CJC-1295?

Accepted Answer

The pharmacology of stopping is better documented than most things about this compound, and all of it is hormone levels. After multiple CJC-1295 doses in healthy adults, mean IGF-I levels remained above baseline for up to 28 days, so the signal carries on for weeks past the final injection. Nothing in the cited literature follows anyone beyond that point. No study among the research behind this page has measured whether a person's own growth hormone output returns to where it started, how long that would take, or whether repeated courses change it at all. A 2026 review of peptides in ageing lists the open items for this class, and they include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy. What is documented is a tail measured in weeks, rather than a recovery curve.

Question 13

What are the documented downsides of CJC-1295?

Accepted Answer

Most of the documented adverse effects belong to the class rather than to this compound. Sorting the class-level record from the handful of findings that name this compound is the work of the CJC-1295 safety page. In the 2006 trials in healthy adults, no serious adverse reactions were reported. That describes two short trials rather than a safety profile. A 2026 review of growth hormone axis peptides lists fluid retention syndromes, musculoskeletal symptoms such as muscle and joint pain, and injection-site reactions. A 2026 critical review of peptide use in sport points to cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability as the risks emerging in human users. The same review records that products are often mislabeled or contaminated. A 2026 review in Sports Medicine states the position for the whole class: rigorous human safety data are scarce, and there is potential for serious harm to patients.

Question 14

Is CJC-1295 approved, and is it legal?

Accepted Answer

No cited record shows an approved use for CJC-1295 anywhere. A 2026 review states the point for performance uses directly, naming the absence of regulatory approval for physique- or performance-related indications. In sport the position is spelled out rather than implied. A 2021 paper opens by stating that the administration of growth hormone releasing hormone and its synthetic analogs is prohibited by the World Anti-Doping Agency. A 2010 forensic analysis puts CJC-1295 itself under Section S2 of the WADA Prohibited List. A 2026 method paper backs that up. It also gives the reason these are hard to catch, citing their in vivo instability, rapid renal clearance, and low urinary concentrations. Banned in sport and unapproved in medicine are two separate facts. Neither one tells you what a national law says about owning a vial.

Question 15

What do the FDA recall records show about CJC-1295?

Accepted Answer

Four Class II recalls of CJC-1295 preparations sit in the FDA enforcement record. Every one of them concerns sterility rather than the compound itself. One covered CJC-1295, 2000 MCG/ML, 5 ML vial, pulled for lack of assurance of sterility due to concerns with production processes which cannot assure sterility of products intended to be sterile. Another covered a CJC-1295 injectable pre-filled syringe, pulled for the same reason. Two of the four were combination vials holding CJC-1295 and ipamorelin together, and those are weighed on the comparison page. A sterility failure is a finding about a production line rather than about the molecule, which is the useful thing to take from it. Separately, a 2010 case records an unknown pharmaceutical preparation whose sequence is consistent with a peptide currently marketed under the name CJC-1295.

Question 16

How is CJC-1295 thought to work?

Accepted Answer

In outline, it borrows the body's own chain of command instead of replacing a hormone. Growth hormone-releasing hormone is made in the brain and travels to the pituitary, where it prompts the release of growth hormone into the blood. CJC-1295 is a long-acting copy of that signal, which is why a 2019 paper describes it as stimulating the production of growth hormone from the pituitary gland. Growth hormone then acts on the liver and other tissues, which put out IGF-1, the messenger most of the later effects are pinned on. That is where the chain turns speculative. A 2026 orthopaedic review states that growth hormone secretagogues including CJC-1295 activate IGF-1 signaling and satellite cell repair, and in the same breath records a current lack of clinical trials. The 2006 trials confirmed the first two links in healthy adults by tracking growth hormone and IGF-I, and everything after that is inferred.

CJC-1295